GATD3A is a protein found in the mitochondria, and it is hypothesized to have the ability to prevent “glycation” by removing substances that lead to the formation of AGEs (Advanced Glycation End products). Many diseases, such as diabetes, Parkinson's disease, and Alzheimer's disease, are all associated with abnormally high levels of AGEs in the body. That’s why GATD3A is worth significant research value. This study explores GATD3A (Glutamine Amidotransferase-like Class 1 Domain 3A). After gene synthesis and protein expression, the protein was produced in large quantities, and its structure and function were investigated. The optimal conditions for protein preparation have been established(25℃, 0.1mM IPTG), and protein crystals were cultivated for structural analysis using X-ray crystallography. Structural analysis was then conducted. The comparison of the structures of GATD3A and other similar proteins was made to identify its active sites (E62, C177). The examination of its basic properties, such as conservation, hydrophilicity, and charge are also finished. Additionally, the optimal pH value (7.0) and other environmental conditions for enzymatic reactions were determined, and enzyme kinetics were calculated(Vmax = 62.11 μM/s、Km = 1286.1 μM、Kcat = 54.48 s-1). In the “deglycation” experiments, GATD3A clearly demonstrated the ability to metabolize MGO. However, GATD3A is a glyoxalase, not a deglycase. Future research is expected to further explore its clinical applications, particularly in removing glycated hemoglobin from diabetic patients.